search
Back to results

The Synergy Disc To Anterior Cervical Discectomy and Fusion

Primary Purpose

Cervical Degenerative Disc Disease

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Anterior Cervical Discectomy & Fusion
Sponsored by
Synergy Spine Solutions
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cervical Degenerative Disc Disease

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18 70 years;
  2. Diagnosis of radiculopathy or myelopathy of the cervical spine, with either radiculopathy symptoms - pain, paresthesia, or paralysis in a specific nerve root distribution C4, C5, C6, or C7, including at least one of the following: arm/shoulder pain (at least 30 mm on 100 mm VAS scale); decreased muscle strength of at least one level on the 0-5 scale described below; abnormal sensation, including hyperesthesia or hypoesthesia; and/or abnormal reflexes; or myelopathy symptoms including positive Romberg evaluation, abnormal heel/toe walk, pathologic hyperreflexia or clonus in lower extremity, positive Babinski, or positive Hoffman's;
  3. Symptomatic at only one level from C3-C4 to C6-C7;
  4. Radiographically determined pathology at level to be treated correlating to primary symptoms, including at least one of the following:

    1. Decreased disc height compared to adjacent levels on radiographic film, CT, or MRI
    2. Degenerative spondylosis on CT or MRI
    3. Disc herniation on CT or MRI.
  5. Neck Disability Index (NDI) score ≥ 30/100;
  6. Unresponsive to non-operative treatment for six weeks, or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment;
  7. Appropriate for treatment using an anterior surgical approach, including having no more than one previous anterior surgical approach to the cervical spine;
  8. Ability and willingness to comply with follow-up regimen; and
  9. Written informed consent given by subject or subject's legally authorized representative.

Exclusion Criteria:

  1. Infection at the site of surgery;
  2. History of, or anticipated treatment for, active systemic infection, including HIV infection or hepatitis C;
  3. Prior attempted or completed cervical spine surgery, except (1) laminoforaminotomy (greater than 6 months prior to scheduled surgical treatment), which includes removal of disc material necessary to perform a nerve root decompression, with less than one-third facetectomy at any level, or (2) a successful single-level anterior cervical fusion (greater than 6 months prior to scheduled surgical treatment);
  4. More than one immobile vertebral level between C1-T1 from any cause, including but not limited to congenital abnormalities, osteoarthritic "spontaneous" fusions, and prior cervical spinal fusions;
  5. Previous trauma to the C3-T1 levels resulting in significant bony or disco-ligamentous cervical spine injury;
  6. Axial neck pain in the absence of other symptoms of radiculopathy or myelopathy justifying the need for surgical intervention;
  7. Radiographic confirmation of severe facet joint disease or degeneration.
  8. Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation) for females or MORES (Male Osteoporosis Risk Estimation Score), will be used to screen patients to determine those patients who require a DEXA bone mineral density measurement. If DEXA is required, exclusion will be defined as a DEXA bone density measured T score ≤ -2.5 (The World Health Organization definition of osteoporosis). DEXA scans within the last 6 months prior to surgical treatment may be used;
  9. Paget's disease, osteomalacia, or any other metabolic bone disease (excluding osteoporosis which is addressed above);
  10. Severe diabetes mellitus requiring daily insulin management;
  11. Active malignancy: a history of any invasive malignancy (except non-melanoma skin cancer), unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years;
  12. Tumor as source of symptoms;
  13. Symptomatic DDD or significant cervical spondylosis at two or more levels;
  14. Marked cervical instability on resting lateral or flexion/extension radiographs demonstrated by:

    1. Translation > 3.5 mm and/or
    2. 11° angular difference to that of either adjacent level;
  15. Known or suspected allergy to cobalt, chromium, molybdenum, titanium, or polyethylene;
  16. Severe myelopathy to the extent that the patient is wheelchair bound;
  17. Congenital canal stenosis resulting in a canal diameter of < 10 mm, as measured by CT or MRI;
  18. Kyphotic segmental angulation of greater than 11 degrees at treatment or adjacent levels;
  19. Arachnoiditis;
  20. Pregnant (verified in patients of childbearing potential by a negative urine pregnancy test when pre-admission testing is obtained), or interested in becoming pregnant during the duration of the study;
  21. Autoimmune disorders that impact the musculoskeletal system (e.g., lupus, rheumatoid arthritis; ankylosing spondylitis);
  22. Congenital bony and/or spinal cord abnormalities that affect spinal stability;
  23. Spinal axis disease (thoracic or lumbar) to the extent that surgical consideration is likely anticipated within 6 months after the cervical procedure;
  24. Other degenerative joint disease (e.g. shoulder, hip, knee) to the extent that surgical consideration is likely anticipated within 6 months after the cervical procedure;
  25. Diseases or conditions that would preclude accurate clinical evaluation (e.g. neuromuscular disorders such as diffuse idiopathic skeletal hyperostosis (DISH));
  26. Medications that could interfere with fusion or other bone/soft tissue healing (e.g. anticipated continued use of systemic steroid medication postoperatively);
  27. Currently experiencing acute episode of major mental illness (psychosis, major affective disorder, or schizophrenia), or manifesting physical symptoms without a diagnosable medical condition to account for the symptoms, which may indicate symptoms of psychological rather than physical origin;
  28. Current or recent history of substance abuse (drug or alcohol) per site PI's determination;
  29. Morbid obesity, defined as body mass index ("BMI") > 40;
  30. Currently using, or planning to use, bone growth stimulators in the cervical spine;
  31. Use of any other investigational drug or medical device within the last 30 days prior to surgery;
  32. Currently a prisoner;
  33. Currently pursuing personal litigation (defined as litigation that will likely influence the patient's ability or willingness to accurately report their treatment outcomes) related to the neck or cervical spine injury; however, involvement in worker's compensation related litigation is not a required exclusion.

Sites / Locations

  • Barrow Brain and Spine
  • HonorHealth Research Institute/Barrow Brain and Spine
  • Todd H. Lanman, M.D.
  • Orthopedic Specialty Institute
  • Institute of Neuro Innovation
  • Anschutz Medical Center
  • Kennedy White Orthopaedic Center
  • Indiana Spine Group
  • Michigan Orthopedic Surgeons
  • Upstate Medical University
  • Hospital for Special Surgery
  • Emerging Medical Research
  • Summit Spine
  • Center for Sports Medicine and Orthopaedic Surgery (CSMO)
  • Central Texas Brain & Spine
  • Austin Neurosurgeons
  • Texas Spine Care Center
  • The Disc Replacement Center
  • Atlantic Brain & Spine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Synergy Disc

Arm Description

The Synergy Disc is a cervical disc prosthesis that can be inserted between C3-C7 in skeletally mature patients after anterior discectomy to provide restoration of motion to the functional spinal unit. The Synergy Disc is designed to restoring kinematics to the cervical spine. The Synergy Disc is intended for use in the cervical spine for reconstruction of the disc following a single level discectomy for intractable radiculopathy and/or myelopathy.

Outcomes

Primary Outcome Measures

NDI
≥ 15-point improvement in NDI Score (out of 100) in subjects at 24 months compared with baseline
Neurological Assessment
Maintenance or improvement in neurological status (motor and sensory only) at 24 months compared to baseline
SSI
No study failure due to secondary surgical interventions (revision, removal, re-operation, supplemental fixation) at the index level
Device Related AE
Absence of major device related adverse events defined as radiographic failure, neurological failure, or failure by adverse event as adjudicated by the CEC.

Secondary Outcome Measures

SF-3
Health Survey (SF-36) at baseline and at each follow-up time-point
VAS
Visual analogue scale (VAS) will be used to evaluate pain where a change of at least 20mm will be considered clinically significant. Neck pain as measured on a 100mm VAS at baseline and at each follow-up time-point. Left and Right arm/shoulder pain as measured on a 100mm VAS at baseline and at each follow-up time-point. Please note, this assessment will include a "Worst" to pool together the left or right arm/shoulder scores with the higher baseline score. VAS Hoarseness on a 100mm scale.
Patient Satisfaction
Patient Satisfaction Questionnaire
BZ Score
Bazaz Dysphagia Score at 24 months compared to baseline
Odom's Criteria
Results at 24 months for the investigational Synergy Disc and at 24 months for the control ACDF will also be categorized by the physician according to Odom's Criteria.

Full Information

First Posted
July 7, 2020
Last Updated
June 1, 2023
Sponsor
Synergy Spine Solutions
Collaborators
MCRA
search

1. Study Identification

Unique Protocol Identification Number
NCT04469231
Brief Title
The Synergy Disc To Anterior Cervical Discectomy and Fusion
Official Title
A Multi-Center, Prospective, Historically Controlled Pivotal Trial Comparing The Safety And Effectiveness Of The Synergy Disc To Anterior Cervical Discectomy And Fusion In Patients With One-Level Symptomatic Cervical Degenerative Disc Disease (DDD).
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 30, 2020 (Actual)
Primary Completion Date
January 1, 2024 (Anticipated)
Study Completion Date
January 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Synergy Spine Solutions
Collaborators
MCRA

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
A multicenter, prospective, non-randomized, historically controlled study. Demonstrate the Synergy Disc is at least as safe and effective as conventional anterior cervical discectomy and fusion (ACDF) to treat cervical degenerative disc disease (DDD) in subjects who are symptomatic at only one level from C3 to C7 that are unresponsive to conservative management. Patients will be evaluated preoperatively, at the time of surgery, and at 6 weeks, 3, 6, 12, and 24 months after surgery. Follow-up will continue annually until the last patient reaches 24-month follow-up. The primary analysis will occur at 24 months.
Detailed Description
The proposed investigation is a prospective, non-randomized, multi-center, historically controlled comparison of the Synergy Disc to the control of conventional anterior cervical discectomy and fusion (ACDF) surgery in patients with cervical DDD. A total of 175 patients will be enrolled to the investigational group not including approximately 15 training cases. The investigational group results will be compared to a historical control data from the ACDF control group, which utilized an identical study design. A statistically rigorous observational study design using propensity score (PS) subclassification will be used to demonstrate covariate balance and enhance the quality of inferences regarding effectiveness and safety relative to ACDF control. After investigational device enrollment is complete, but before most investigational device subjects have reached their 24-month endpoint, a data set containing only baseline covariates of prospectively enrolled investigational device patients and historical ACDF control patients will be constructed. The propensity score methods detailed below will be implemented by an outcomes-blinded statistician. A Propensity Score Memo summarizing the proposed observational design will be developed and submitted for review by stakeholders including FDA. The outcomes-blinded statistician will remain blinded until after consensus is achieved that the design is acceptable. This will allow for additional outcomes-blinded PS modeling if required. The objective of this clinical trial is to demonstrate the Synergy Disc is at least as safe and effective as conventional ACDF to treat cervical DDD in subjects who are symptomatic at only one level from C3 to C7 that are unresponsive to conservative management.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Degenerative Disc Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
A multicenter, prospective, non-randomized, historically controlled study.
Masking
None (Open Label)
Allocation
N/A
Enrollment
175 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Synergy Disc
Arm Type
Experimental
Arm Description
The Synergy Disc is a cervical disc prosthesis that can be inserted between C3-C7 in skeletally mature patients after anterior discectomy to provide restoration of motion to the functional spinal unit. The Synergy Disc is designed to restoring kinematics to the cervical spine. The Synergy Disc is intended for use in the cervical spine for reconstruction of the disc following a single level discectomy for intractable radiculopathy and/or myelopathy.
Intervention Type
Device
Intervention Name(s)
Anterior Cervical Discectomy & Fusion
Other Intervention Name(s)
ACDF
Intervention Description
ACDF
Primary Outcome Measure Information:
Title
NDI
Description
≥ 15-point improvement in NDI Score (out of 100) in subjects at 24 months compared with baseline
Time Frame
24 Month
Title
Neurological Assessment
Description
Maintenance or improvement in neurological status (motor and sensory only) at 24 months compared to baseline
Time Frame
24 Month
Title
SSI
Description
No study failure due to secondary surgical interventions (revision, removal, re-operation, supplemental fixation) at the index level
Time Frame
24 Month
Title
Device Related AE
Description
Absence of major device related adverse events defined as radiographic failure, neurological failure, or failure by adverse event as adjudicated by the CEC.
Time Frame
24 Month
Secondary Outcome Measure Information:
Title
SF-3
Description
Health Survey (SF-36) at baseline and at each follow-up time-point
Time Frame
6 Week, 3, 6, 12, and 24 Month
Title
VAS
Description
Visual analogue scale (VAS) will be used to evaluate pain where a change of at least 20mm will be considered clinically significant. Neck pain as measured on a 100mm VAS at baseline and at each follow-up time-point. Left and Right arm/shoulder pain as measured on a 100mm VAS at baseline and at each follow-up time-point. Please note, this assessment will include a "Worst" to pool together the left or right arm/shoulder scores with the higher baseline score. VAS Hoarseness on a 100mm scale.
Time Frame
6 Week, 3, 6, 12, and 24 Month
Title
Patient Satisfaction
Description
Patient Satisfaction Questionnaire
Time Frame
6 Week, 3, 6, 12, and 24 Month
Title
BZ Score
Description
Bazaz Dysphagia Score at 24 months compared to baseline
Time Frame
6 Week, 3, 6, 12, and 24 Month
Title
Odom's Criteria
Description
Results at 24 months for the investigational Synergy Disc and at 24 months for the control ACDF will also be categorized by the physician according to Odom's Criteria.
Time Frame
6 Week, 3, 6, 12, and 24 Month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 70 years; Diagnosis of radiculopathy or myelopathy of the cervical spine, with either radiculopathy symptoms - pain, paresthesia, or paralysis in a specific nerve root distribution C4, C5, C6, or C7, including at least one of the following: arm/shoulder pain (at least 30 mm on 100 mm VAS scale); decreased muscle strength of at least one level on the 0-5 scale described below; abnormal sensation, including hyperesthesia or hypoesthesia; and/or abnormal reflexes; or myelopathy symptoms including positive Romberg evaluation, abnormal heel/toe walk, pathologic hyperreflexia or clonus in lower extremity, positive Babinski, or positive Hoffman's; Symptomatic at only one level from C3-C4 to C6-C7; Radiographically determined pathology at level to be treated correlating to primary symptoms, including at least one of the following: Decreased disc height compared to adjacent levels on radiographic film, CT, or MRI Degenerative spondylosis on CT or MRI Disc herniation on CT or MRI. Neck Disability Index (NDI) score ≥ 30/100; Unresponsive to non-operative treatment for six weeks, or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment; Appropriate for treatment using an anterior surgical approach, including having no more than one previous anterior surgical approach to the cervical spine; Ability and willingness to comply with follow-up regimen; and Written informed consent given by subject or subject's legally authorized representative. Exclusion Criteria: Infection at the site of surgery; History of, or anticipated treatment for, active systemic infection, including HIV infection or hepatitis C; Prior attempted or completed cervical spine surgery, except (1) laminoforaminotomy (greater than 6 months prior to scheduled surgical treatment), which includes removal of disc material necessary to perform a nerve root decompression, with less than one-third facetectomy at any level, or (2) a successful single-level anterior cervical fusion (greater than 6 months prior to scheduled surgical treatment); More than one immobile vertebral level between C1-T1 from any cause, including but not limited to congenital abnormalities, osteoarthritic "spontaneous" fusions, and prior cervical spinal fusions; Previous trauma to the C3-T1 levels resulting in significant bony or disco-ligamentous cervical spine injury; Axial neck pain in the absence of other symptoms of radiculopathy or myelopathy justifying the need for surgical intervention; Radiographic confirmation of severe facet joint disease or degeneration. Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation) for females or MORES (Male Osteoporosis Risk Estimation Score), will be used to screen patients to determine those patients who require a DEXA bone mineral density measurement. If DEXA is required, exclusion will be defined as a DEXA bone density measured T score ≤ -2.5 (The World Health Organization definition of osteoporosis). DEXA scans within the last 6 months prior to surgical treatment may be used; Paget's disease, osteomalacia, or any other metabolic bone disease (excluding osteoporosis which is addressed above); Severe diabetes mellitus requiring daily insulin management; Active malignancy: a history of any invasive malignancy (except non-melanoma skin cancer), unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years; Tumor as source of symptoms; Symptomatic DDD or significant cervical spondylosis at two or more levels; Marked cervical instability on resting lateral or flexion/extension radiographs demonstrated by: Translation > 3.5 mm and/or 11° angular difference to that of either adjacent level; Known or suspected allergy to cobalt, chromium, molybdenum, titanium, or polyethylene; Severe myelopathy to the extent that the patient is wheelchair bound; Congenital canal stenosis resulting in a canal diameter of < 10 mm, as measured by CT or MRI; Kyphotic segmental angulation of greater than 11 degrees at treatment or adjacent levels; Arachnoiditis; Pregnant (verified in patients of childbearing potential by a negative urine pregnancy test when pre-admission testing is obtained), or interested in becoming pregnant during the duration of the study; Autoimmune disorders that impact the musculoskeletal system (e.g., lupus, rheumatoid arthritis; ankylosing spondylitis); Congenital bony and/or spinal cord abnormalities that affect spinal stability; Spinal axis disease (thoracic or lumbar) to the extent that surgical consideration is likely anticipated within 6 months after the cervical procedure; Other degenerative joint disease (e.g. shoulder, hip, knee) to the extent that surgical consideration is likely anticipated within 6 months after the cervical procedure; Diseases or conditions that would preclude accurate clinical evaluation (e.g. neuromuscular disorders such as diffuse idiopathic skeletal hyperostosis (DISH)); Medications that could interfere with fusion or other bone/soft tissue healing (e.g. anticipated continued use of systemic steroid medication postoperatively); Currently experiencing acute episode of major mental illness (psychosis, major affective disorder, or schizophrenia), or manifesting physical symptoms without a diagnosable medical condition to account for the symptoms, which may indicate symptoms of psychological rather than physical origin; Current or recent history of substance abuse (drug or alcohol) per site PI's determination; Morbid obesity, defined as body mass index ("BMI") > 40; Currently using, or planning to use, bone growth stimulators in the cervical spine; Use of any other investigational drug or medical device within the last 30 days prior to surgery; Currently a prisoner; Currently pursuing personal litigation (defined as litigation that will likely influence the patient's ability or willingness to accurately report their treatment outcomes) related to the neck or cervical spine injury; however, involvement in worker's compensation related litigation is not a required exclusion.
Facility Information:
Facility Name
Barrow Brain and Spine
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85013
Country
United States
Facility Name
HonorHealth Research Institute/Barrow Brain and Spine
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85251
Country
United States
Facility Name
Todd H. Lanman, M.D.
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90210
Country
United States
Facility Name
Orthopedic Specialty Institute
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Institute of Neuro Innovation
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
Anschutz Medical Center
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Kennedy White Orthopaedic Center
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34232
Country
United States
Facility Name
Indiana Spine Group
City
Carmel
State/Province
Indiana
ZIP/Postal Code
46032
Country
United States
Facility Name
Michigan Orthopedic Surgeons
City
Southfield
State/Province
Michigan
ZIP/Postal Code
48033
Country
United States
Facility Name
Upstate Medical University
City
East Syracuse
State/Province
New York
ZIP/Postal Code
13057
Country
United States
Facility Name
Hospital for Special Surgery
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Emerging Medical Research
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27704
Country
United States
Facility Name
Summit Spine
City
Portland
State/Province
Oregon
ZIP/Postal Code
97225
Country
United States
Facility Name
Center for Sports Medicine and Orthopaedic Surgery (CSMO)
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37404
Country
United States
Facility Name
Central Texas Brain & Spine
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Facility Name
Austin Neurosurgeons
City
Austin
State/Province
Texas
ZIP/Postal Code
78746
Country
United States
Facility Name
Texas Spine Care Center
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78231
Country
United States
Facility Name
The Disc Replacement Center
City
West Jordan
State/Province
Utah
ZIP/Postal Code
84088
Country
United States
Facility Name
Atlantic Brain & Spine
City
Reston
State/Province
Virginia
ZIP/Postal Code
20190
Country
United States

12. IPD Sharing Statement

Learn more about this trial

The Synergy Disc To Anterior Cervical Discectomy and Fusion

We'll reach out to this number within 24 hrs